Additional TR study on Phase 2 study of Trastuzumab Deruxtecan in the neoadjuvant treatment for patients with HER2 positive gastric and gastroesophageal junction adenocarcinoma
Not Applicable
Recruiting
- Conditions
- HER2 positive gastric and gastroesophageal junction adenocarcinoma
- Registration Number
- JPRN-jRCT1030210361
- Lead Sponsor
- Shitara Kohei
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
Patients enrolled in the Phase 2 study of Trastuzumab Deruxtecan in the neoadjuvant treatment for patients with HER2 positive gastric and gastroesophageal junction adenocarcinoma who have consented for the study will be included.
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method